T. Rowe Price Associates
MGNX icon

T. Rowe Price Associates’s MacroGenics MGNX Stock Holding History

T. Rowe Price Associates’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Buy
+51,560
New +$195K ﹤0.01% 2950
2025
Q2 		– Sell
-25,652
Closed -$33K – 3112
2025
Q1 		$33K Sell
25,652
-460,335
-95% -$1.2M ﹤0.01% 2975
2024
Q4 		$1.58M Sell
485,987
-768,249
-61% -$2.77M ﹤0.01% 1763
2024
Q3 		$4.13M Sell
1,254,236
-82,784
-6% -$323K ﹤0.01% 1358
2024
Q2 		$5.68M Sell
1,337,020
-1,101,030
-45% -$10.7M ﹤0.01% 1192
2024
Q1 		$35.9M Buy
2,438,050
+2,409,237
+8,362% +$36.4M ﹤0.01% 817
2023
Q4 		$278K Sell
28,813
-4,198
-13% -$29K ﹤0.01% 2414
2023
Q3 		$154K Buy
33,011
+8,034
+32% +$40K ﹤0.01% 2572
2023
Q2 		$134K Buy
24,977
+234
+0.9% +$1.44K ﹤0.01% 2636
2023
Q1 		$178K Buy
24,743
+976
+4% +$5.88K ﹤0.01% 2557
2022
Q4 		$159K Buy
23,767
+5,612
+31% +$30.8K ﹤0.01% 2601
2022
Q3 		$63K Sell
18,155
-6,833
-27% -$26.1K ﹤0.01% 2801
2022
Q2 		$74K Buy
24,988
+300
+1% +$1.58K ﹤0.01% 2813
2022
Q1 		$218K Buy
24,688
+1,421
+6% +$15.7K ﹤0.01% 2680
2021
Q4 		$373K Sell
23,267
-14,200
-38% -$267K ﹤0.01% 2515
2021
Q3 		$785K Buy
37,467
+4,400
+13% +$106K ﹤0.01% 2163
2021
Q2 		$888K Sell
33,067
-22
-0.1% -$644 ﹤0.01% 2122
2021
Q1 		$1.05M Buy
33,089
+3,677
+13% +$89.3K ﹤0.01% 2022
2020
Q4 		$672K Buy
29,412
+12,106
+70% +$279K ﹤0.01% 2111
2020
Q3 		$436K Buy
+17,306
New +$473K ﹤0.01% 2146
2019
Q1 		– Sell
-2,250,287
Closed -$28.6M – 2551
2018
Q4 		$28.6M Sell
2,250,287
-32,859
-1% -$551K ﹤0.01% 1024
2018
Q3 		$49M Buy
2,283,146
+47,175
+2% +$1.01M 0.01% 919
2018
Q2 		$46.2M Sell
2,235,971
-23,020
-1% -$519K 0.01% 927
2018
Q1 		$56.8M Buy
+2,258,991
New +$54.9M 0.01% 824
2016
Q4 		– Sell
-8,380
Closed -$251K – 2562
2016
Q3 		$251K Hold
8,380
– – ﹤0.01% 2282
2016
Q2 		$226K Buy
+8,380
New +$189K ﹤0.01% 2281
2015
Q1 		– Sell
-32,426
Closed -$1.14M – 2561
2014
Q4 		$1.14M Buy
+32,426
New +$808K ﹤0.01% 1684

Other funds holding MGNX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Associates's MGNX Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in MacroGenics (MGNX) in Q2 2026: 51,560 shares worth $239K. The stake represents ﹤0.01% of the portfolio and ranks #2950 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in MGNX as recently as Q1 2025.

T. Rowe Price Associates first reported a position in MGNX in Q4 2014 and has held it in 27 quarters since. The position peaked at $56.8M in Q1 2018. 122 funds tracked by Wall St. Rank hold MGNX as of Q2 2026.

  • T. Rowe Price Associates held 51,560 shares of MacroGenics worth $239K as of Q2 2026.
  • MacroGenics was a new T. Rowe Price Associates position in Q2 2026.
  • MacroGenics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2950 holding.
  • T. Rowe Price Associates first reported a position in MacroGenics in Q4 2014 and has held it in 27 quarters since.
  • T. Rowe Price Associates's MacroGenics position peaked at $56.8M in Q1 2018.
  • 122 funds tracked by Wall St. Rank held MacroGenics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.